<DOC>
	<DOCNO>NCT02759354</DOCNO>
	<brief_summary>To describe long-term persistence Hepatitis B pertussis antibody responses healthy 4- 5 Year old child previously vaccinate VAXELIS INFANRIX hexa</brief_summary>
	<brief_title>Long-term Persistence Hepatitis B Pertussis Antibody Responses Healthy 4- 5 Year Old Children Previously Vaccinated With VAXELIS INFANRIX Hexa</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Inclusion Criteria 1 . Healthy child either gender , receive complete 3dose primary series complete 2 dose primary series follow toddler dose VAXELIS INFANRIX hexa part V419007 V419008 study respectively ; 2 . Informed consent sign subject 's parent ( ) legal representative . 1 . Subject receive dose HB contain vaccine time study vaccine V419007 V419008 study ; 2 . Subject history diagnosis ( clinical , serological microbiological ) HB virus infection V419007 V419008 study ; 3 . Subject receive dose pertussis contain vaccine completion V419008 study ; 4 . Subject history diagnosis ( clinical , serological microbiological ) infection due pertussis completion V419008 study ; 5 . Participation time study enrolment 4 week precede study enrolment another clinical study investigate vaccine , drug medical device , medical procedure ; 6 . Subject receive immunoglobulin , blood bloodderived product within 3 month prior inclusion ; 7 . Receipt immunosuppressive therapy immunemodifying drug , anticancer chemotherapy radiation therapy since completion V419007 V419008 study ; 8 . Subject suspect known blood dyscrasia , leukemia , lymphoma type malignant neoplasm affect haematopietic lymphatic system since completion V419007 V419008 study .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Immune response</keyword>
</DOC>